Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Mosunetuzumab with Lenalidomide Augmentation As First-Line Therapy for Follicular (FL) and Marginal Zone Lymphoma (MZL)

Adam J. Olszewski, Scott F. Huntington, Rajat Bannerji, Thomas A. Ollila, Jessica McMahon, Patrycja M Dubielecka

Blood (2022) 140 (Supplement 1): 6492–6493.

https://doi.org/10.1182/blood-2022-157463

Published: 2022

Journal Articles

Impact of Race and Social Determinants of Health on Outcomes in Patients with Aggressive B-Cell Lymphomas Treated with Chimeric Antigen Receptor T-Cell (CART) Therapy

Blood (2022) 140 (Supplement 1): 10955–10957.

https://doi.org/10.1182/blood-2022-160431

Published: 2022

Journal Articles

Outcomes of Primary Central Nervous System Lymphoma (PCNSL) Treated with Immunochemotherapy or Chemotherapy Alone: Analysis of the National Cancer Data Base 2013-2018

Thomas A. Ollila, Rashida Taher, Stephen Grado, Adam J. Olszewski

Blood (2022) 140 (Supplement 1): 3773–3774.

https://doi.org/10.1182/blood-2022-156596

Published: 2022

Journal Articles

Double Hit/Double Expressor Lymphomas: A Multicenter Analysis of Survival Outcomes with CD19-Directed CAR T-Cell Therapy

Blood (2022) 140 (Supplement 1): 375–377.

https://doi.org/10.1182/blood-2022-163438

Published: 2022

Journal Articles

Consensus Cachexia Criteria Are Independently Linked to Progression Free and Overall Survival in Multi-Site Analysis of Patients with Aggressive B-Cell Lymphomas Treated with CAR T-Cell Therapy

Blood (2022) 140 (Supplement 1): 2416–2418.

https://doi.org/10.1182/blood-2022-163822

Published: 2022

Journal Articles

Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions

Victor Manuel Orellana-Noia, Daniel R. Reed, Ashley Alesia McCook, Jeremy Michael Sen, Christian M. Barlow, Mary-Kate Malecek, Marcus Watkins, Brad S. Kahl, Michael A. Spinner, Ranjana Advani, Timothy J. Voorhees, Anson Snow, Natalie Sophia Grover, Amy Ayers, Jason Romancik, Yuxin Liu, Scott F. Huntington, Julio C. Chavez, Hayder Saeed, Aleksandr Lazaryan, Vikram Raghunathan, Stephen E. Spurgeon, Thomas A. Ollila, Christopher Del Prete, Adam Olszewski, Emily C. Ayers, Daniel J. Landsburg, Benjamin Echalier, Jun Lee, Manali Kamdar, Paolo F. Caimi, Timothy Fu, Jieqi Liu, Kevin A. David, Hanan Alharthy, Jennie Law, Reem Karmali, Harsh Shah, Deborah M. Stephens, Ajay Major, Alexandra E. Rojek, Sonali M. Smith, Amulya Yellala, Avyakta Kallam, Shazi Nakhoda, Nadia Khan, Mohammad Ahsan Sohail, Brian T. Hill, Odeth Barrett-Campbell, Frederick Lansigan, Jeffrey Switchenko, Jonathon Cohen, Craig A. Portell

Blood (2022) 139 (3): 413–423.

https://doi.org/10.1182/blood.2021012888

Published: 2022

Includes: Supplemental data

Journal Articles

Outcomes and Treatment Patterns in Patients with Aggressive B-Cell Lymphoma after Failure of Anti-CD19 CAR T-Cell Therapy

Blood (2021) 138 (Supplement 1): 884.

https://doi.org/10.1182/blood-2021-147433

Published: 2021

Journal Articles

Practice Patterns Pre-CART for Aggressive B-Cell Lymphomas: Patient Selection and Real World Salvage and Bridging Practices

Blood (2021) 138 (Supplement 1): 532.

https://doi.org/10.1182/blood-2021-147033

Published: 2021

Journal Articles

Factors Associated with Seroconversion after COVID-19 Vaccination in Patients with Hematologic Malignancies

Thomas A. Ollila, Rebecca Masel, John L Reagan, Kimberly Paiva, Shaolei Lu, Ralph Rogers, Adam Zayac, Rashida Taher, Inna Yakirevich, Rabin Niroula, Peter Barth, Adam J. Olszewski

Blood (2021) 138 (Supplement 1): 3511.

https://doi.org/10.1182/blood-2021-144304

Published: 2021

Journal Articles

CDKN2A Deletions Define an Unfavorable Subgroup within the MYD88/CD79B (MCD) Subtype of Diffuse Large B-Cell Lymphoma (DLBCL) and Are Mutually Exclusive with TP53 mutations

Adam J. Olszewski, Radwa Sharaf, Chelsea Marcus, Habibe Kurt, Lee A Albacker, Jo-Anne Vergilio, Thomas A. Ollila

Blood (2021) 138 (Supplement 1): 2392.

https://doi.org/10.1182/blood-2021-146335

Published: 2021

Journal Articles

Genomic subtypes may predict the risk of central nervous system recurrence in diffuse large B-cell lymphoma

Thomas A. Ollila, Habibe Kurt, Jozal Waroich, John Vatkevich, Ashlee Sturtevant, Nimesh R. Patel, Patrycja M. Dubielecka, Diana O. Treaba, Adam J. Olszewski

Blood (2021) 137 (8): 1120–1124.

https://doi.org/10.1182/blood.2020007236

Published: 2021

Includes: Supplemental data

Journal Articles

EBV-Positive Primary CNS Lymphomas in Older Patients: Incidence, Characteristics, Tumor Pathology, and Outcomes across a Large Multicenter Cohort

Prashasti Agrawal, Kevin A. David, MD, Zhengming Chen, PhD MPH, MS, Suchitra Sundaram, MD, Seo-Hyun Kim, MD, Ryan Vaca, MD, Yong Lin, PhD, Samuel Singer, MD, Mary-Kate Malecek, MD, Jordan Carter, MD, Adam Zayac, MD, Myung Sun Kim, MD, Nishitha Reddy, MD, Alma Habib, MD, Christopher Strouse, MD, Jerome Graber, MD, Veronika Bachanova, MD PhD, Mazie Tsang, MD, Ajay Major, MDMBA, David A. Bond, MD, Angel Mier-Hicks, MD, Pallawi Torka, MD, Priya Rajakumar, MD, Parameswaran Venugopal, MD, Michael Glantz, MD PhD, Samuel Goldlust, MD, Rahul Matnani, MD, Pallavi Kumar, MD, Thomas A Ollila, MD, Johnny Cai, DO, Stephen E. Spurgeon, MD, Alex G Sieg, MD MS, Joseph Cleveland, MD, Narendranath Epperla, MDMS, Reem Karmali, MDMSc, Seema Naik, MD, Sonali M. Smith, MD, James L. Rubenstein, MD PhD, Brad S. Kahl, MD, Amy Chadburn, MD, Andrew M. Evens, DO,MMSc, Peter Martin, FRCPC, MD MS

Blood (2020) 136 (Supplement 1): 4–6.

https://doi.org/10.1182/blood-2020-138885

Published: 2020

Journal Articles

Vincristine Sulfate Liposome Injection (VSLI) with Bendamustine and Rituximab As First-Line Therapy for Indolent B-Cell Lymphomas: A Phase 1 Study

Thomas A Ollila, MD, James Butera, MD, Pamela C Egan, MD, John L Reagan, MD, Anthony G Thomas, DO, Inna Yakirevich, NP, Kelsey MacKinnon, Jeannine Margolis, Valerie Rosati, Jessica McMahon, RN, Jordan Robison, CRA, Adam J Olszewski, MD

Blood (2020) 136 (Supplement 1): 15–16.

https://doi.org/10.1182/blood-2020-134054

Published: 2020

Journal Articles

CNS Prophylaxis during Front-Line Therapy in Aggressive Non-Hodgkin Lymphomas: Real-World Outcomes and Practice Patterns from 19 US Academic Institutions

Victor M. Orellana-Noia, MD, Daniel R Reed, MD, Jeremy M Sen, PharmD, BCOP, Christian Barlow, MD, Mary-Kate Malecek, MD, Brad S. Kahl, MD, Michael A Spinner, MD, Ranjana Advani, MD, Timothy J Voorhees, MD, Anson Snow, MD, Natalie S Grover, MD, Amy Ayers, MPH, Jason T. Romancik, MD, Yuxin Liu, MD, Scott F. Huntington, MD MPH, Julio C. Chavez, MD, Hayder Saeed, MD, Aleksandr Lazaryan, MDPhDMPH, Vikram Raghunathan, MD, Stephen E. Spurgeon, MD, Thomas A Ollila, MD, Christopher Del Prete, MD, Adam J Olszewski, MD, Emily C. Ayers, MD, Daniel J. Landsburg, MD, Benjamin Echalier, Jun Lee, Manali Kamdar, MD, Paolo F Caimi, MD, Timothy Fu, MD, Jieqi Liu, MD, Kevin A. David, MD, Hanan Alharthy, MD, Jennie Y. Law, MD, Reem Karmali, MDMSc, Harsh Shah, DO, Deborah M. Stephens, DO, Ajay Major, MDMBA, Alexandra E Rojek, MD, Sonali M. Smith, MD, Amulya Yellala, MBBS, Avyakta Kallam, MD, Shazia Nakhoda, MD, Nadia Khan, MD, Jonathon B. Cohen, MDMS, Craig A. Portell, MD

Blood (2020) 136 (Supplement 1): 27–28.

https://doi.org/10.1182/blood-2020-134798

Published: 2020

Journal Articles

Cerebrospinal Fluid (CSF) Analysis of Tumor-Specific Cell-Free DNA (cfDNA) As a Diagnostic and Prognostic Tool for Central Nervous System (CNS) Invasion in Lymphoma

Adam J Olszewski, MD, Anna D Chorzalska, PhD, Max Petersen, Thomas A Ollila, MD, Adam Zayac, MD, Habibe Kurt, MD, Diana O Treaba, MD, John L Reagan, MD, Andrew Hsu, MD, Pamela C Egan, MD, James Butera, MD, William Rafelson, MDMBA, Rabin Niroula, MBBS, John Vatkevich, Jordan Robison, CRA, Ilyas Sahin, MD, Chelsea D Mullins, BS, Patrycja M Dubielecka, PhD

Blood (2020) 136 (Supplement 1): 21–22.

https://doi.org/10.1182/blood-2020-134757

Published: 2020

Journal Articles

Real World (RW) Outcomes and Prognostication of Older Patients with Primary Central Nervous System Lymphoma (PCNSL) in the Contemporary Era

Blood (2020) 136 (Supplement 1): 24–26.

https://doi.org/10.1182/blood-2020-136551

Published: 2020

Journal Articles

Exposure to Ibritumomab Tiuxetan and Incidence of Treatment-Related Myeloid Neoplasms Among Older Patients with B-Cell Lymphoma: A Population-Based Study

Mengyang Di, MD PhD, Thomas A Ollila, MD, Adam J Olszewski, MD

Blood (2019) 134 (Supplement_1): 3477.

https://doi.org/10.1182/blood-2019-121959

Published: 2019

Journal Articles

Bendamustine-Rituximab Does Not Improve Survival over Rituximab Monotherapy for Older Patients with Nodal or Splenic Marginal Zone Lymphoma

Adam J Olszewski, MD, Thomas A Ollila, MD, John L. Reagan, MD

Blood (2019) 134 (Supplement_1): 2824.

https://doi.org/10.1182/blood-2019-121841

Published: 2019

Journal Articles

BrUOG 345: Fractionated Gemtuzumab Ozogamicin Followed By Non-Engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia

Adam Zayac, MD, Pamela C Egan, MD, Thomas A Ollila, MD, Adam J Olszewski, MD, Peter Barth, MD, Matthew I. Quesenberry, MD, James Butera, MD, Loren D. Fast, PhD, Rabin Niroula, MBBS, Peter J. Quesenberry, MD, John L Reagan, MD

Blood (2019) 134 (Supplement_1): 4460.

https://doi.org/10.1182/blood-2019-123789

Published: 2019

Journal Articles

Tumor-Specific Cell-Free DNA (cfDNA) in the Cerebrospinal Fluid (CSF) Detects Cytologically Occult Central Nervous System (CNS) Involvement in Aggressive Lymphomas

Adam J Olszewski, MD, Anna D Chorzalska, PhD, Diana O Treaba, MD, John L Reagan, MD, Pamela C Egan, MD, Habibe Kurt, MD, James Butera, MD, William Rafelson, MDMBA, Alexander C Mohler, MD MS, Thomas A Ollila, MD, Rabin Niroula, MBBS, Jordan Robison, CRA, Chelsea D Mullins, BS, Patrycja M Dubielecka, PhD

Blood (2019) 134 (Supplement_1): 2800.

https://doi.org/10.1182/blood-2019-125475

Published: 2019

NARROW

Mosunetuzumab with Lenalidomide Augmentation As First-Line Therapy for Follicular (FL) and Marginal Zone Lymphoma (MZL)

Impact of Race and Social Determinants of Health on Outcomes in Patients with Aggressive B-Cell Lymphomas Treated with Chimeric Antigen Receptor T-Cell (CART) Therapy

Outcomes of Primary Central Nervous System Lymphoma (PCNSL) Treated with Immunochemotherapy or Chemotherapy Alone: Analysis of the National Cancer Data Base 2013-2018

Double Hit/Double Expressor Lymphomas: A Multicenter Analysis of Survival Outcomes with CD19-Directed CAR T-Cell Therapy

Consensus Cachexia Criteria Are Independently Linked to Progression Free and Overall Survival in Multi-Site Analysis of Patients with Aggressive B-Cell Lymphomas Treated with CAR T-Cell Therapy

Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions

Outcomes and Treatment Patterns in Patients with Aggressive B-Cell Lymphoma after Failure of Anti-CD19 CAR T-Cell Therapy

Practice Patterns Pre-CART for Aggressive B-Cell Lymphomas: Patient Selection and Real World Salvage and Bridging Practices

Factors Associated with Seroconversion after COVID-19 Vaccination in Patients with Hematologic Malignancies

CDKN2A Deletions Define an Unfavorable Subgroup within the MYD88/CD79B (MCD) Subtype of Diffuse Large B-Cell Lymphoma (DLBCL) and Are Mutually Exclusive with TP53 mutations

Genomic subtypes may predict the risk of central nervous system recurrence in diffuse large B-cell lymphoma

EBV-Positive Primary CNS Lymphomas in Older Patients: Incidence, Characteristics, Tumor Pathology, and Outcomes across a Large Multicenter Cohort

Vincristine Sulfate Liposome Injection (VSLI) with Bendamustine and Rituximab As First-Line Therapy for Indolent B-Cell Lymphomas: A Phase 1 Study

CNS Prophylaxis during Front-Line Therapy in Aggressive Non-Hodgkin Lymphomas: Real-World Outcomes and Practice Patterns from 19 US Academic Institutions

Cerebrospinal Fluid (CSF) Analysis of Tumor-Specific Cell-Free DNA (cfDNA) As a Diagnostic and Prognostic Tool for Central Nervous System (CNS) Invasion in Lymphoma

Real World (RW) Outcomes and Prognostication of Older Patients with Primary Central Nervous System Lymphoma (PCNSL) in the Contemporary Era

Exposure to Ibritumomab Tiuxetan and Incidence of Treatment-Related Myeloid Neoplasms Among Older Patients with B-Cell Lymphoma: A Population-Based Study

Bendamustine-Rituximab Does Not Improve Survival over Rituximab Monotherapy for Older Patients with Nodal or Splenic Marginal Zone Lymphoma

BrUOG 345: Fractionated Gemtuzumab Ozogamicin Followed By Non-Engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia

Tumor-Specific Cell-Free DNA (cfDNA) in the Cerebrospinal Fluid (CSF) Detects Cytologically Occult Central Nervous System (CNS) Involvement in Aggressive Lymphomas

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only